← Eichor
Study identifier: NCT06694740 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

Condition: Post-aggressive Immunosuppression · Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6 · Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C  ·  Sponsor: Assistance Publique - Hôpitaux de Paris

PhasePhase 2/Phase 3
Planned participants170
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).

This description comes directly from the study's public registry record.

Talk to the study team

Charles De ROQUETAILLADE, MD  ·  01 49 95 55 68  ·  charles.de-roquetaillade@aphp.fr

Benjamin CHOUSTERMAN, Professor  ·  01 49 95 85 18  ·  benjamin.chousterman@aphp.fr

Always discuss trial participation with your own doctor first.

Locations (2)

Dr de RoquetailladeParis, FranceRecruiting
Pr DépretParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06694740